Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Bullboard Posts
Comment by ISRAELon Mar 20, 2020 6:29pm
1168 Views
Post# 30832262

RE:🇮🇱BGU Coronavirus Task Forceℹ

RE:🇮🇱BGU Coronavirus Task Forceℹ
DR. LIOR CARMON is Vaxil Bio's FOUNDER
PHD, IMMUNOLOGY, WEIZMANN | MBA, 
BEN-GURION UNIVERSITY | Inventor on 7 patents
 
Dr. Lior Carmon founded Vaxil, prior to which he served as VP at Ester Neuroscience (acquired by Amarin Corp. Dr. Carmon also worked as an investor with Clal (CBI), Israel’s largest biotech fund. Dr. Carmon currently sits on the Board of the Israeli Immunology Society (IIS). https://vaxil-bio.dev.seoprrank.com/board-and-executives/
 

DoTheMath wrote: Ben-Gurion University of the Negev President Prof. Daniel Chamovitz launched the BGU Coronavirus (COVID-19) Task Force last Thursday morning to harness the University's brainpower and ingenuity to help cope with the coronavirus pandemic. During a meeting attended by over 50 scientists from departments across the University, Chamovitz declared that the University would set aside resources to bring the most promising projects to fruition. 
 
"It is our moral obligation to contribute to coping with this pandemic," President Chamovitz wrote in the letter urging all BGU researchers to join the task force. 
 
During the launch meeting, over a dozen ideas were raised by members of departments from different faculties who then broke off into working groups. Several researchers contributed ideas via video conferencing from self-quarantine. In some cases, ongoing projects were quickly repurposed. In others, new collaborations sprung up around the discussion tables this morning. 
 
As everyday life around the world has been affected, the effects of the coronavirus extend beyond the search for a vaccine. In addition to the University's virologists, BGU scientists and students will address the public health, public policy, engineering, information systems, economic, psychological, technological, tourism and educational challenges. 
 
"Since the outbreak of this coronavirus, it has become an international crisis that affects individuals, families, communities and countries around the world," President Chamovitz wrote, "I am turning to you, our researchers, to make the coronavirus crisis and its repercussions your top priority, to be creative and practical in order to achieve significant contributions to the national and international challenges that stand before us." C-19 info
 

 

Bullboard Posts